Ergomed plc: Interim results for six months ended 30 June 2021
Guildford-based Ergomed, a company focused on providing specialised services to the global pharmaceutical industry, has announced its unaudited interim results for the six months ended 30 June 2021.
Key financial highlights include: total revenue of 38.8% over H1 2020 has gone up to £56.0 million (up 48.1% in constant currency), with adjusted EBITDA at £12.1 million, up 33% (H1 2020: £9.1 million). Furthermore, basic adjusted earnings per share of 16.8p have gone up 48.7% (H1 2020: 11.3p) and the net cash of £24.6 million has gone up 74.5% (30 June 2020: £14.1 million).
Some of the operational highlights are: net new sales awards have gone up 50.8% and North America revenues have gone up 70.8% to £35.5 million.
About Ergomed plc
Guildford-based Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance, and medical information.
